Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells 67,687 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 67,687 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The stock was sold at an average price of $34.84, for a total transaction of $2,358,215.08. Following the completion of the transaction, the chief operating officer now owns 751,243 shares of the company’s stock, valued at $26,173,306.12. This trade represents a 8.27 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Wednesday, February 12th, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77.
• On Tuesday, January 21st, Melissa Baird sold 67,687 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.35, for a total value of $1,986,613.45.

Hims & Hers Health Stock Down 8.8 %

Shares of HIMS stock opened at $29.11 on Friday. Hims & Hers Health, Inc. has a 12 month low of $11.20 and a 12 month high of $72.98. The company’s fifty day simple moving average is $39.88 and its 200-day simple moving average is $29.48. The firm has a market cap of $6.47 billion, a PE ratio of 66.15 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on HIMS shares. Morgan Stanley cut Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their price objective for the stock from $42.00 to $60.00 in a report on Tuesday, February 18th. Leerink Partners upped their target price on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research report on Tuesday, February 25th. Citigroup reissued a “sell” rating and issued a $27.00 target price on shares of Hims & Hers Health in a research note on Thursday, March 6th. Canaccord Genuity Group boosted their target price on Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Finally, Needham & Company LLC increased their price target on shares of Hims & Hers Health from $31.00 to $61.00 and gave the company a “buy” rating in a research report on Tuesday, February 25th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and an average price target of $37.31.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HIMS. SlateStone Wealth LLC boosted its holdings in shares of Hims & Hers Health by 4.0% in the 4th quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock valued at $257,000 after buying an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its position in Hims & Hers Health by 100.0% during the fourth quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Hims & Hers Health by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after acquiring an additional 628 shares during the last quarter. Cim LLC grew its position in shares of Hims & Hers Health by 1.0% in the 4th quarter. Cim LLC now owns 71,869 shares of the company’s stock valued at $1,738,000 after acquiring an additional 694 shares during the period. Finally, Quest Partners LLC increased its stake in shares of Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after purchasing an additional 807 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.